A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Launched by AOP ORPHAN PHARMACEUTICALS AG · Jun 4, 2024
Trial Information
Current as of March 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed informed consent for study participation in NIS
- Exclusion Criteria:
- • 1. Lost to follow-up patients of TripleTRE study
- • 2. Patients who discontinued all medicinal PAH treatments (e.g. after successful lung transplantation)
- • 3. Patients who withdrew from the initial TripleTRE trial due to significant non-compliance with trial requirements (not adhering to therapy, not coming to hospital visits)
About Aop Orphan Pharmaceuticals Ag
AOP Orphan Pharmaceuticals AG is a specialized biopharmaceutical company focused on developing innovative therapies for rare and complex diseases. With a commitment to addressing unmet medical needs, the company engages in the research, development, and commercialization of orphan drugs that aim to improve the quality of life for patients with debilitating conditions. AOP Orphan leverages its expertise in various therapeutic areas, including hematology, oncology, and neurology, to advance its clinical programs and collaborate with healthcare professionals and institutions worldwide. Driven by a patient-centric approach, AOP Orphan Pharmaceuticals AG strives to deliver transformative solutions that enhance treatment options for underserved populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Szeged, , Hungary
Madrid, , Spain
Barcelona, , Spain
Vienna, , Austria
Vienna, , Austria
Greifswald, , Germany
Strasbourg, , France
Praha, , Czechia
Rome, , Italy
Olomouc, , Czechia
Berlin, , Germany
Linz, , Austria
Paris, , France
Dresden, , Germany
Budapest, , Hungary
Kraków, , Poland
Otwock, , Poland
Bucharest, , Romania
Târgu Mureş, , Romania
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
